News
We provide the latest news from the world of economics and finance
We provide the latest news from the world of economics and finance
(RTTNews) - Regenxbio Inc. (RGNX) shares are gaining more than 7 percent on Tuesday morning trade after the clinical-stage biotechnology reported additional interim safety and efficacy data in the Phase I/II Affinity Duchenne trial of RGX-202 in patients of 4-11 years old with Duchenne muscular dystrophy.
The company said while there is an insufficient level of data in boys above 7 years, RGX-202 at dose level 2 demonstrated significantly increased microdystrophin expression in a 12-year-old patient.
Currently, shares are at $23.10, up 7.68 percent from the previous close of $21.36 on a volume of 880,468.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@just2trade.online
